1. Generics Bulletin
  2. >>Business
  3. >>Deals

Xbrane And Biogen Ally On Certolizumab Pegol Biosimilar

Xbrane CEO Martin Åmark Highlights Potential For Xcimzane Rival To Cimzia

 
• By Dave Wallace

Xbrane Biopharma and Biogen have struck a licensing deal for Xbrane’s Xcimzane certolizumab pegol proposed biosimilar rival to Cimzia. In the wake of the announcement, Xbrane CEO Martin Åmark offered details on the partnership as well as the product’s commercial potential.

Certolizumab Pegol green background
Xbrane has secured Biogen as a partner on its Xcimzane certolizumab pegol biosimilar • Source: molekuul.be / Alamy Stock Photo

Xbrane Biopharma and Biogen have struck a global licensing and commercialization deal for Xbrane’s Xcimzane (certolizumab pegol) proposed biosimilar rival to Cimzia that is currently at the pre-clinical stage. Through the agreement, Biogen will gain exclusive global regulatory, manufacturing and commercial rights to Xcimzane and will be the marketing authorization holder for the biosimilar.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Hikma Secures US Rights To Novugen’s Generic Trametinib

 
• By Adam Zamecnik

The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.

Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech

 
• By Adam Zamecnik

After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.